Financial news

DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 2019 (english)

06/12/2018 - 22:35

Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 2019

DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast
Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative
guidance for 2019

06-Dec-2018 / 22:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fresenius Medical Care, the world's largest provider of dialysis products
and services, has decided to update the market early on its indicative
preliminary assumptions for the business development in 2019. For 2019,
Fresenius Medical Care currently broadly assumes solid comparable1 revenue
growth and the comparable1 net income to be around the level of fiscal year

Fresenius Medical Care is currently reviewing all factors as part of its
budgeting process and plans to publish the guidance for 2019, at the usual
level of detail, along with the company's fiscal year 2018 results, which
are planned to be released on February 20, 2019.

[1] "comparable" is on a constant currency basis and reflects an adjustment
for those effects that are as per the company's view not related to the
company's operating business performance such as, for example, the effects
of IFRS 16, sizeable portfolio changes like the divestiture of Sound
Inpatient Physicians Holdings, the pending acquisition of NxStage Medical
Inc., or other effects of one-time nature like FCPA-related charges or the
cost of the 2018 U.S. ballot initiatives. For the preliminary indicative
2019 guidance the "comparable" 2018 basis translates roughly at current
currencies for revenue in a range of 15,850 - 16,050 EUR million and for net
income in a range of 1,350 - 1,365 EUR million. This is subject to
fluctuations in the currency rates in the fourth quarter of 2018.

Person making the notification:
Dr. Dominik Heger
SVP Investor Relations & Corporate Communications
P. +49 6172 609 2601

Fresenius Medical Care is the world's largest provider of products and
services for individuals with renal diseases of which around 3.2 million
patients worldwide regularly undergo dialysis treatment. Through its network
of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis
treatments for 329,085 patients around the globe. Fresenius Medical Care is
also the leading provider of dialysis products such as dialysis machines or
dialyzers. Along with its core business, the company provides related
medical services in the field of Care Coordination. Fresenius Medical Care
is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock
Exchange (FMS).

For more information visit the company's website at

The envisaged date of February 20, 2019 for announcement on the guidance for
2019 is subject to compliance with applicable laws, i.e. if applicable legal
regimes so demand, the publication may occur at an earlier point in time.


06-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at


   Language:    English
   Company:     Fresenius Medical Care AG & Co. KGaA
                Else-Kröner-Straße 1
                61352 Bad Homburg
   Phone:       +49 (0) 6172- 609 2525
   Fax:         +49 (0) 6172- 609 2301
   ISIN:        DE0005785802
   WKN:         578580
   Indices:     DAX
   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated
                Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
                Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg
                Stock Exchange

   End of Announcement    DGAP News Service

755287 06-Dec-2018 CET/CEST


Weiterführende Inhalte

Weiterführende Inhalte